Skip to main content
Fig. 5 | Breast Cancer Research

Fig. 5

From: Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy

Fig. 5

Overall survival calculated using the date of start of everolimus exemestane treatment: a Kaplan-Meier curves for patients receiving everolimus exemestane as second-line treatment, stratified by prior therapy; b Kaplan-Meier curves for patients receiving everolimus exemestane as third-line treatment, stratified by prior therapy

Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us